Carsten Buhmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1696314/publications.pdf

Version: 2024-02-01

77 papers 2,408 citations

304743

22

h-index

233421 45 g-index

86 all docs

86 docs citations

86 times ranked 2925 citing authors

#	Article	IF	CITATIONS
1	Prevalence, clinical presentations and impact on relationship of sexual dysfunction in Parkinson's Disease. International Review of Neurobiology, 2022, 162, 1-19.	2.0	2
2	Ageâ€Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (<scp>MARKâ€PD</scp>). Movement Disorders, 2022, 37, 435-436.	3.9	9
3	Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypesÂof Parkinson's disease in the MARK-PD study. Journal of Neural Transmission, 2022, 129, 295-300.	2.8	10
4	Comparison of Montreal cognitive assessment and Mattis dementia rating scale in the preoperative evaluation of subthalamic stimulation in Parkinson's disease. PLoS ONE, 2022, 17, e0265314.	2.5	1
5	Diabetes, Glycated Hemoglobin (<scp>HbA1c)</scp> , and Neuroaxonal Damage in Parkinson's Disease (<scp>MARKâ€PD Study</scp>). Movement Disorders, 2022, 37, 1299-1304.	3.9	22
6	Impact of COVID-19 Pandemic on (Health) Care Situation of People with Parkinson's Disease in Germany (Care4PD). Brain Sciences, 2022, 12, 62.	2.3	7
7	Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice. Journal of Neural Transmission, 2022, 129, 1201-1217.	2.8	23
8	Short pulse and directional thalamic deep brain stimulation have differential effects in parkinsonian and essential tremor. Scientific Reports, 2022, 12, 7251.	3.3	4
9	The ability of the eating assessment tool-10 to detect penetration and aspiration in Parkinson's disease. European Archives of Oto-Rhino-Laryngology, 2021, 278, 1661-1668.	1.6	8
10	Cannabis in Parkinson's Disease: The Patients' View. Journal of Parkinson's Disease, 2021, 11, 309-321.	2.8	22
11	Dysphagia Screening in Parkinson's Disease. A diagnostic accuracy crossâ€sectional study investigating the applicability of the Gugging Swallowing Screen (GUSS). Neurogastroenterology and Motility, 2021, 33, e14034.	3.0	7
12	Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study. Parkinsonism and Related Disorders, 2021, 85, 5-10.	2.2	10
13	Cardiac manifestation is evident in chorea-acanthocytosis but different from McLeod syndrome. Parkinsonism and Related Disorders, 2021, 88, 90-95.	2.2	4
14	Short Pulse and Conventional Deep Brain Stimulation Equally Improve the Parkinsonian Gait Disorder. Journal of Parkinson's Disease, 2021, 11, 1455-1464.	2.8	12
15	F28â€Novel mutations and findings in a cohort of McLeod neuroacanthocytosis, an X-linked HD phenocopy. , 2021, , .		O
16	Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease― Movement Disorders, 2021, 36, 273-274.	3.9	1
17	Nine-years follow-up of cavernoma located in basal ganglia mimicking Parkinson's disease. Clinical Neurology and Neurosurgery, 2020, 190, 105664.	1.4	1
18	Sex Disparities in the Self-Evaluation of Subthalamic Deep Brain Stimulation Effects on Mood and Personality in Parkinson's Disease Patients. Frontiers in Neurology, 2020, 11, 776.	2.4	8

#	Article	IF	CITATIONS
19	Specialized Staff for the Care of People with Parkinson's Disease in Germany: An Overview. Journal of Clinical Medicine, 2020, 9, 2581.	2.4	20
20	Reply to: "Nâ€Terminal Proâ€Bâ€Type Natriuretic Peptide Levels in Parkinson's Disease― Movement Disorder 2020, 35, 1888-1888.	rs _{3.9}	0
21	Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany. Journal of Clinical Medicine, 2020, 9, 1455.	2.4	15
22	Management of Pain in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, S37-S48.	2.8	38
23	Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease. Movement Disorders, 2020, 35, 1863-1868.	3.9	18
24	Pallidal lead placement in dystonia: leads of non-responders are contained within an anatomical range defined by responders. Journal of Neurology, 2020, 267, 1663-1671.	3.6	16
25	A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation. Movement Disorders, 2020, 35, 1471-1475.	3.9	20
26	Impact of simultaneous subthalamic and nigral stimulation on dysphagia in Parkinson's disease. Annals of Clinical and Translational Neurology, 2020, 7, 628-638.	3.7	10
27	Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis. Parkinsonism and Related Disorders, 2020, 80, 28-31.	2.2	6
28	Discussing sexuality with Parkinson's disease patients: a multinational survey among neurologists. Journal of Neural Transmission, 2019, 126, 1273-1280.	2.8	11
29	The challenge of pain in the pharmacological management of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2019, 20, 1847-1854.	1.8	16
30	Swallowing speed is no adequate predictor of aspiration in Parkinson's disease. Neurogastroenterology and Motility, 2019, 31, e13713.	3.0	5
31	Evidence for the use of cannabinoids in Parkinson's disease. Journal of Neural Transmission, 2019, 126, 913-924.	2.8	25
32	Gait Training in Virtual Reality: Short-Term Effects of Different Virtual Manipulation Techniques in Parkinson's Disease. Cells, 2019, 8, 419.	4.1	36
33	Quantitative Sensory Testing (QST) in Drug-NaÃ⁻ve Patients with Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 369-378.	2.8	8
34	Mapping stimulation-induced beneficial and adverse effects in the subthalamic area of essential tremor patients. Parkinsonism and Related Disorders, 2019, 64, 150-155.	2.2	12
35	Pill swallowing in Parkinson's disease: A prospective study based on flexible endoscopic evaluation of swallowing. Parkinsonism and Related Disorders, 2019, 62, 51-56.	2.2	30
36	Conditioned pain modulation in drug-naÃ⁻ve patients with de novo Parkinson's disease. Neurological Research and Practice, 2019, 1, 27.	2.0	2

#	Article	IF	Citations
37	Phase-Dependent Suppression of Beta Oscillations in Parkinson's Disease Patients. Journal of Neuroscience, 2019, 39, 1119-1134.	3.6	89
38	Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 62, 141-147.	2.2	12
39	Is the Munich dysphagia Test–Parkinson's disease (MDT-PD) a valid screening tool for patients at risk for aspiration?. Parkinsonism and Related Disorders, 2019, 61, 138-143.	2.2	17
40	Predictive clinical factors for penetration and aspiration in Parkinson's disease. Neurogastroenterology and Motility, 2019, 31, e13524.	3.0	34
41	Pearls & Dy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy. Neurology, 2018, 90, 482-485.	1.1	10
42	Spatio-temporal dynamics of cortical drive to human subthalamic nucleus neurons in Parkinson's disease. Neurobiology of Disease, 2018, 112, 49-62.	4.4	58
43	Levodopa-induced dystonia in a patient with possible progressive supranuclear palsy with progressive gait freezing. Journal of the Neurological Sciences, 2018, 388, 139-140.	0.6	1
44	Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study. Dysphagia, 2018, 33, 41-50.	1.8	114
45	Drooling is no early sign of dysphagia in Parkinson′s disease. Neurogastroenterology and Motility, 2018, 30, e13259.	3.0	21
46	Stress Management Training (SMT) Improves Coping of Tremor-Boosting Psychosocial Stressors and Depression in Patients with Parkinson's Disease: A Controlled Prospective Study. Parkinson's Disease, 2018, 2018, 1-12.	1.1	5
47	The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care. Journal of Neural Transmission, 2018, 125, 1461-1472.	2.8	9
48	Thalamic short pulse stimulation diminishes adverse effects in essential tremor patients. Neurology, 2018, 91, e704-e713.	1.1	35
49	Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. Journal of Neurology, 2017, 264, 758-769.	3.6	74
50	Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. Journal of Neural Transmission, 2017, 124, 1005-1013.	2.8	6
51	Altered neural responses to heat pain in drug-naive patients with Parkinson disease. Pain, 2017, 158, 1408-1416.	4.2	11
52	Retinal degeneration in progressive supranuclear palsy measured by optical coherence tomography and scanning laser polarimetry. Scientific Reports, 2017, 7, 5357.	3.3	14
53	The impact of Parkinson disease on patients' sexuality and relationship. Journal of Neural Transmission, 2017, 124, 983-996.	2.8	37
54	Impact of Combined Subthalamic Nucleus and Substantia Nigra Stimulation on Neuropsychiatric Symptoms in Parkinson's Disease Patients. Parkinson's Disease, 2017, 2017, 1-14.	1.1	7

#	Article	IF	Citations
55	STN-DBS Reduces Saccadic Hypometria but Not Visuospatial Bias in Parkinson's Disease Patients. Frontiers in Behavioral Neuroscience, 2016, 10, 85.	2.0	12
56	Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. Journal of Neural Transmission, 2016, 123, 57-64.	2.8	117
57	Detection of retinal changes in idiopathic Parkinson's disease using highâ€resolution optical coherence tomography and heidelberg retina tomography. Acta Ophthalmologica, 2015, 93, e578-84.	1.1	31
58	Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in Parkinson's disease. Acta Ophthalmologica, 2015, 93, e672-7.	1.1	21
59	Impact of Deep Brain Stimulation on Daily Routine Driving Practice in Patients with Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-9.	1.1	5
60	Subthalamic deep brain stimulation improves auditory sensory gating deficit in Parkinson's disease. Clinical Neurophysiology, 2015, 126, 565-574.	1.5	24
61	Synchronized cortico-subthalamic beta oscillations in Parkin-associated Parkinson's disease. Clinical Neurophysiology, 2015, 126, 2241-2243.	1.5	9
62	Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus. NeuroImage: Clinical, 2015, 9, 436-449.	2.7	36
63	Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients. PLoS ONE, 2015, 10, e0135287.	2.5	19
64	Could deep brain stimulation help with driving for patients with Parkinson's?. Expert Review of Medical Devices, 2014, 11, 427-429.	2.8	7
65	Effect of subthalamic nucleus deep brain stimulation on driving in Parkinson disease. Neurology, 2014, 82, 32-40.	1.1	19
66	Asymmetric pallidal neuronal activity in patients with cervical dystonia. Frontiers in Systems Neuroscience, 2014, 8, 15.	2.5	59
67	Activity Parameters of Subthalamic Nucleus Neurons Selectively Predict Motor Symptom Severity in Parkinson's Disease. Journal of Neuroscience, 2014, 34, 6273-6285.	3.6	157
68	Deep Brain Stimulation of the Ventrolateral Thalamic Base and Posterior Subthalamic Area in Dystonic Head Tremor. Acta Neurochirurgica Supplementum, 2013, 117, 67-72.	1.0	10
69	STN Stimulation in General Anaesthesia: Evidence Beyond â€~Evidence-Based Medicine'., 2013, 117, 19-25.		22
70	Waking up the brain: a case study of stimulation-induced wakeful unawareness during anaesthesia. Progress in Brain Research, 2009, 177, 125-145.	1.4	24
71	Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Neurobiology of Disease, 2004, 15, 160-170.	4.4	88
72	Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Movement Disorders, 2003, 18, 219-221.	3.9	54

#	Article	IF	CITATIONS
73	Increased Lipid Peroxidation in Cerebrospinal Fluid and Plasma from Patients with Creutzfeldt–Jakob Disease. Neurobiology of Disease, 2002, 10, 150-156.	4.4	30
74	Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy. Acta Neurologica Scandinavica, 2002, 106, 236-239.	2.1	17
75	Characterization of four lipoprotein classes in human cerebrospinal fluid. Journal of Lipid Research, 2001, 42, 1143-1151.	4.2	243
76	Characterization of four lipoprotein classes in human cerebrospinal fluid. Journal of Lipid Research, 2001, 42, 1143-51.	4.2	191
77	Increased lipoprotein oxidation in alzheimer's disease. Free Radical Biology and Medicine, 2000, 28, 351-360.	2.9	181